The Impact of the Announcement of the Vaccine's Success on the Company's Stock
DOI:
https://doi.org/10.54097/e51yf054Keywords:
COVID -19; ARIMA Model; Stock Price; Predictions.Abstract
This article examines the impact of Pfizer's announcement of the vaccine's success within the framework of the ongoing COVID-19 situation. By constructing ARIMA model, this paper compares Pfizer's stock price change after the vaccine announcement with the forecast unannounced stock price change, so as to judge the impact on the company. This paper found that the company's stock price rose significantly, proving that the company can promote the development of vaccine research and development by announcing a positive image. This paper covers the economic and public health areas to study the impact of the company, and the use of time series to predict. Through the research conclusion, this paper suggests that investors may prefer to choose a more positive image and impact of the enterprise investment, in order to protect returns. At the same time, leaders can also lead the enterprise to create a positive image, to bring more support and opportunities.
Downloads
References
Rohrich, R. J., Hamilton, K. L., Avashia, Y. J., & Savetsky, I. L. The COVID-19 Pandemic: Changing Lives and Lessons Learned[J/OL]. Plastic and Reconstructive Surgery - Global Open, 2020: e2854.
World Bank. COVID-19 Policy Response Notes for Vietnam [M/OL]. 2020.
Van Barneveld K, Quinlan M, Kriesler P, et al. The COVID-19 pandemic: Lessons on building more equal and sustainable societies[J]. The economic and labour relations review, 2020, 31(2): 133-157.
Tsao S F, Chen H, Tisseverasinghe T, et al. What social media told us in the time of COVID-19: a scoping review[J]. The Lancet Digital Health, 2021, 3(3): e175-e194.
Bavel J J V, Baicker K, Boggio P S, et al. Using social and behavioural science to support COVID-19 pandemic response[J]. Nature human behaviour, 2020, 4(5): 460-471.
Carro B. SARS-CoV-2 mechanisms of action and impact on human organism, risk factors and potential treatments. An exhaustive survey[J]. All Life, 2021, 14(1): 894-947.
Bloom D E, Cadarette D. Infectious disease threats in the twenty-first century: strengthening the global response[J]. Frontiers in immunology, 2019, 10: 445106.
Martin-Fumadó C, Aragonès L, Areste M E, et al. Medico-legal, ethical and deontological considerations of vaccination against COVID-19 in healthcare professionals[J]. Medicina Clínica (English Edition), 2021, 157(2): 79-84.
Agostinis G, Grépin K A, Kamradt-Scott A, et al. COVID-19 and IR scholarship: one profession, many voices[J]. International Studies Review, 2021, 23(2): 302-345.
Dimitropoulou D, Theofilakou A. Explaining the cross-country differences in the economic fallout during the COVID-19 pandemic crisis[J]. Economic Bulletin, 2021 (53): 29-48.
Donthu N, Gustafsson A. Effects of COVID-19 on business and research[J]. Journal of business research, 2020, 117: 284-289.
Shah D, Isah H, Zulkernine F. Stock market analysis: A review and taxonomy of prediction techniques[J]. International Journal of Financial Studies, 2019, 7(2): 26.
Nazar F A. COVID cure or perpetual vaccination?: 30 cheap effective treatments of COVID-19 & variants, like ivermectin, or never-ending compulsory injection, with unsafe, genotoxic, infertilizing, injuring, crippling, handicapping, lethal, inefficient, ineffective, abortion-tainted, abortive, unethical, experimental genetic-hacks, deceivingly called vaccines instead of haccines? Scientific proof of the COVID PLANdemic with 2000 peer reviewed published references[J]. 2021.
Hao F, Xiao Q, Chon K. COVID-19 and China’s hotel industry: Impacts, a disaster management framework, and post-pandemic agenda[J]. International journal of hospitality management, 2020, 90: 102636.
Boro E, Stoll B. Barriers to COVID-19 health products in low-and middle-income countries during the COVID-19 pandemic: A rapid systematic review and evidence synthesis[J]. Frontiers in public health, 2022, 10: 928065.
da Fonseca E M, Shadlen K C, Bastos F I. The politics of COVID-19 vaccination in middle-income countries: Lessons from Brazil[J]. Social Science & Medicine, 2021, 281: 114093.
Wirtz V J, Hogerzeil H V, Gray A L, et al. Essential medicines for universal health coverage[J]. The Lancet, 2017, 389(10067): 403-476.s
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
